Entero Therapeutics Inc ENTO

Healthcare Biotechnology

Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

NDAQ:ENTO - Post by User

Entero Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Oct 31, 2022 10:05am

87 Views

Post# 35059838

FWBI ..... What did I tell everyone in my last post?

It's pretty obvious what Mr. M is doing

Just hang in there....keep your powder dry.....I'd say this could go quite a bit lower

But I will be there like "Joe the Bear" with lard in his hair !!!!

Cheap paper makes the world go around !!!

Not selling ... Cheers !

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks